Global Hormone Deficiency Market

Hormone Deficiency Comprehensive Study by Application (Hospitals, Clinics), Medication (Genotropin, Humatrope, Norditropin, Other), Types of Hormonal Disorders (Adrenal, Parathyroid, Pancreas, Pituitary, Thyroid), Symptoms (Dry skin, Puffy face, Frequent urination, Depression, Infertility) Players and Region - Global Market Outlook to 2027

Hormone Deficiency Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Hormone Deficiency
Hormone deficiency, also known as dwarfism or pituitary dwarfism, is a condition caused by insufficient levels of growth hormone in the body. GHD children have abnormally short stature but normal body proportions. GHD can be present at birth or develop later in life (acquired). Human growth hormone (hGH) or somatotropin is a peptide hormone that is responsible in humans for cell reproduction, growth stimulation, and cell regeneration. Human growth hormone (GH) deficiency occurs when the pituitary gland is unable to synthesise enough hGH. This deficiency is treated by administering recombinant hGH subcutaneously. Human growth hormone deficiency can be caused by a variety of genetic disorders, including Turner syndrome and Prader-Willi syndrome, resulting in shorter-than-average height and delayed puberty.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)


The market for Hormone Deficiency is highly competitive with several global as well as local players in the market. The global players are trying various strategies such as product innovation and using various marketing strategies to gain a higher market share. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Hormone Deficiency market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Merck Serono (Germany), Pfizer (United States), Novo Nordisk (Denmark), F. Hoffmann-La Roche (Switzerland), Anhui Anke Biotechnology (Group) (China), BioPartners (Switzerland), Eli Lilly (United States), Ferring Pharmaceuticals (Switzerland), GeneScience Pharmaceuticals (China), Ipsen (France) and Teva Pharmaceutical Industries (Israel) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Hormone Deficiency market by , Application (Hospitals and Clinics) and Region.



On the basis of geography, the market of Hormone Deficiency has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Medication, the sub-segment i.e. Genotropin will boost the Hormone Deficiency market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Types of Hormonal Disorders, the sub-segment i.e. Adrenal will boost the Hormone Deficiency market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Symptoms, the sub-segment i.e. Dry skin will boost the Hormone Deficiency market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

On 25 May 2022, Aeterna Zentaris Inc., announced that Ghryvelin (macimorelin), the first oral test approved for diagnosing Growth Hormone Deficiency in adults , is available to healthcare professionals across Europe. This availability is possible thanks to Aeterna’s licensing partner, Consilient Health, Ltd., a privately owned pharmaceutical company focused on commercializing medicines in Europe and Middle East.
On 26 August 2021, The FDA approved the first once-weekly formulation of somatropin for children with growth hormone deficiency, according to an industry press release. Lonapegsomatropin-tcgd injection (Skytrofa, Ascendis) is approved for children who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone.

Market Drivers
  • Increasing Prevalence Of Growth Disorders
  • Surge In Number Of Geriatric Population

Opportunities
  • Surge In Healthcare Expenditure
  • Rising Awareness Level Among Individual For Hormone Deficiency

Restraints
  • High Cost Associated With The Treatment Will Obstruct The Growth Rate Of Market
  • Increasing In Side Effects Of Hormone Deficiency

Challenges
  • Lack Of Advanced Healthcare Infrastructure In Developing Countries
  • Companies Have To Comply With FDA Regulation


Key Target Audience
New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Application
  • Hospitals
  • Clinics
By Medication
  • Genotropin
  • Humatrope
  • Norditropin
  • Other

By Types of Hormonal Disorders
  • Adrenal
  • Parathyroid
  • Pancreas
  • Pituitary
  • Thyroid

By Symptoms
  • Dry skin
  • Puffy face
  • Frequent urination
  • Depression
  • Infertility

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence Of Growth Disorders
      • 3.2.2. Surge In Number Of Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Lack Of Advanced Healthcare Infrastructure In Developing Countries
      • 3.3.2. Companies Have To Comply With FDA Regulation
    • 3.4. Market Trends
      • 3.4.1. Increase In The Number Of Research And Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hormone Deficiency, by Application, Medication, Types of Hormonal Disorders, Symptoms and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Hormone Deficiency (Value)
      • 5.2.1. Global Hormone Deficiency by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Clinics
      • 5.2.2. Global Hormone Deficiency by: Medication (Value)
        • 5.2.2.1. Genotropin
        • 5.2.2.2. Humatrope
        • 5.2.2.3. Norditropin
        • 5.2.2.4. Other
      • 5.2.3. Global Hormone Deficiency by: Types of Hormonal Disorders (Value)
        • 5.2.3.1. Adrenal
        • 5.2.3.2. Parathyroid
        • 5.2.3.3. Pancreas
        • 5.2.3.4. Pituitary
        • 5.2.3.5. Thyroid
      • 5.2.4. Global Hormone Deficiency by: Symptoms (Value)
        • 5.2.4.1. Dry skin
        • 5.2.4.2. Puffy face
        • 5.2.4.3. Frequent urination
        • 5.2.4.4. Depression
        • 5.2.4.5. Infertility
      • 5.2.5. Global Hormone Deficiency Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Hormone Deficiency (Price)
  • 6. Hormone Deficiency: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck Serono (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novo Nordisk (Denmark)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. F. Hoffmann-La Roche (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Anhui Anke Biotechnology (Group) (China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. BioPartners (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Eli Lilly (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Ferring Pharmaceuticals (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. GeneScience Pharmaceuticals (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Ipsen (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Teva Pharmaceutical Industries (Israel)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Hormone Deficiency Sale, by Application, Medication, Types of Hormonal Disorders, Symptoms and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Hormone Deficiency (Value)
      • 7.2.1. Global Hormone Deficiency by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Clinics
      • 7.2.2. Global Hormone Deficiency by: Medication (Value)
        • 7.2.2.1. Genotropin
        • 7.2.2.2. Humatrope
        • 7.2.2.3. Norditropin
        • 7.2.2.4. Other
      • 7.2.3. Global Hormone Deficiency by: Types of Hormonal Disorders (Value)
        • 7.2.3.1. Adrenal
        • 7.2.3.2. Parathyroid
        • 7.2.3.3. Pancreas
        • 7.2.3.4. Pituitary
        • 7.2.3.5. Thyroid
      • 7.2.4. Global Hormone Deficiency by: Symptoms (Value)
        • 7.2.4.1. Dry skin
        • 7.2.4.2. Puffy face
        • 7.2.4.3. Frequent urination
        • 7.2.4.4. Depression
        • 7.2.4.5. Infertility
      • 7.2.5. Global Hormone Deficiency Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Hormone Deficiency (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hormone Deficiency: by Application(USD Million)
  • Table 2. Hormone Deficiency Hospitals , by Region USD Million (2016-2021)
  • Table 3. Hormone Deficiency Clinics , by Region USD Million (2016-2021)
  • Table 4. Hormone Deficiency: by Medication(USD Million)
  • Table 5. Hormone Deficiency Genotropin , by Region USD Million (2016-2021)
  • Table 6. Hormone Deficiency Humatrope , by Region USD Million (2016-2021)
  • Table 7. Hormone Deficiency Norditropin , by Region USD Million (2016-2021)
  • Table 8. Hormone Deficiency Other , by Region USD Million (2016-2021)
  • Table 9. Hormone Deficiency: by Types of Hormonal Disorders(USD Million)
  • Table 10. Hormone Deficiency Adrenal , by Region USD Million (2016-2021)
  • Table 11. Hormone Deficiency Parathyroid , by Region USD Million (2016-2021)
  • Table 12. Hormone Deficiency Pancreas , by Region USD Million (2016-2021)
  • Table 13. Hormone Deficiency Pituitary , by Region USD Million (2016-2021)
  • Table 14. Hormone Deficiency Thyroid , by Region USD Million (2016-2021)
  • Table 15. Hormone Deficiency: by Symptoms(USD Million)
  • Table 16. Hormone Deficiency Dry skin , by Region USD Million (2016-2021)
  • Table 17. Hormone Deficiency Puffy face , by Region USD Million (2016-2021)
  • Table 18. Hormone Deficiency Frequent urination , by Region USD Million (2016-2021)
  • Table 19. Hormone Deficiency Depression , by Region USD Million (2016-2021)
  • Table 20. Hormone Deficiency Infertility , by Region USD Million (2016-2021)
  • Table 21. South America Hormone Deficiency, by Country USD Million (2016-2021)
  • Table 22. South America Hormone Deficiency, by Application USD Million (2016-2021)
  • Table 23. South America Hormone Deficiency, by Medication USD Million (2016-2021)
  • Table 24. South America Hormone Deficiency, by Types of Hormonal Disorders USD Million (2016-2021)
  • Table 25. South America Hormone Deficiency, by Symptoms USD Million (2016-2021)
  • Table 26. Brazil Hormone Deficiency, by Application USD Million (2016-2021)
  • Table 27. Brazil Hormone Deficiency, by Medication USD Million (2016-2021)
  • Table 28. Brazil Hormone Deficiency, by Types of Hormonal Disorders USD Million (2016-2021)
  • Table 29. Brazil Hormone Deficiency, by Symptoms USD Million (2016-2021)
  • Table 30. Argentina Hormone Deficiency, by Application USD Million (2016-2021)
  • Table 31. Argentina Hormone Deficiency, by Medication USD Million (2016-2021)
  • Table 32. Argentina Hormone Deficiency, by Types of Hormonal Disorders USD Million (2016-2021)
  • Table 33. Argentina Hormone Deficiency, by Symptoms USD Million (2016-2021)
  • Table 34. Rest of South America Hormone Deficiency, by Application USD Million (2016-2021)
  • Table 35. Rest of South America Hormone Deficiency, by Medication USD Million (2016-2021)
  • Table 36. Rest of South America Hormone Deficiency, by Types of Hormonal Disorders USD Million (2016-2021)
  • Table 37. Rest of South America Hormone Deficiency, by Symptoms USD Million (2016-2021)
  • Table 38. Asia Pacific Hormone Deficiency, by Country USD Million (2016-2021)
  • Table 39. Asia Pacific Hormone Deficiency, by Application USD Million (2016-2021)
  • Table 40. Asia Pacific Hormone Deficiency, by Medication USD Million (2016-2021)
  • Table 41. Asia Pacific Hormone Deficiency, by Types of Hormonal Disorders USD Million (2016-2021)
  • Table 42. Asia Pacific Hormone Deficiency, by Symptoms USD Million (2016-2021)
  • Table 43. China Hormone Deficiency, by Application USD Million (2016-2021)
  • Table 44. China Hormone Deficiency, by Medication USD Million (2016-2021)
  • Table 45. China Hormone Deficiency, by Types of Hormonal Disorders USD Million (2016-2021)
  • Table 46. China Hormone Deficiency, by Symptoms USD Million (2016-2021)
  • Table 47. Japan Hormone Deficiency, by Application USD Million (2016-2021)
  • Table 48. Japan Hormone Deficiency, by Medication USD Million (2016-2021)
  • Table 49. Japan Hormone Deficiency, by Types of Hormonal Disorders USD Million (2016-2021)
  • Table 50. Japan Hormone Deficiency, by Symptoms USD Million (2016-2021)
  • Table 51. India Hormone Deficiency, by Application USD Million (2016-2021)
  • Table 52. India Hormone Deficiency, by Medication USD Million (2016-2021)
  • Table 53. India Hormone Deficiency, by Types of Hormonal Disorders USD Million (2016-2021)
  • Table 54. India Hormone Deficiency, by Symptoms USD Million (2016-2021)
  • Table 55. South Korea Hormone Deficiency, by Application USD Million (2016-2021)
  • Table 56. South Korea Hormone Deficiency, by Medication USD Million (2016-2021)
  • Table 57. South Korea Hormone Deficiency, by Types of Hormonal Disorders USD Million (2016-2021)
  • Table 58. South Korea Hormone Deficiency, by Symptoms USD Million (2016-2021)
  • Table 59. Australia Hormone Deficiency, by Application USD Million (2016-2021)
  • Table 60. Australia Hormone Deficiency, by Medication USD Million (2016-2021)
  • Table 61. Australia Hormone Deficiency, by Types of Hormonal Disorders USD Million (2016-2021)
  • Table 62. Australia Hormone Deficiency, by Symptoms USD Million (2016-2021)
  • Table 63. Rest of Asia-Pacific Hormone Deficiency, by Application USD Million (2016-2021)
  • Table 64. Rest of Asia-Pacific Hormone Deficiency, by Medication USD Million (2016-2021)
  • Table 65. Rest of Asia-Pacific Hormone Deficiency, by Types of Hormonal Disorders USD Million (2016-2021)
  • Table 66. Rest of Asia-Pacific Hormone Deficiency, by Symptoms USD Million (2016-2021)
  • Table 67. Europe Hormone Deficiency, by Country USD Million (2016-2021)
  • Table 68. Europe Hormone Deficiency, by Application USD Million (2016-2021)
  • Table 69. Europe Hormone Deficiency, by Medication USD Million (2016-2021)
  • Table 70. Europe Hormone Deficiency, by Types of Hormonal Disorders USD Million (2016-2021)
  • Table 71. Europe Hormone Deficiency, by Symptoms USD Million (2016-2021)
  • Table 72. Germany Hormone Deficiency, by Application USD Million (2016-2021)
  • Table 73. Germany Hormone Deficiency, by Medication USD Million (2016-2021)
  • Table 74. Germany Hormone Deficiency, by Types of Hormonal Disorders USD Million (2016-2021)
  • Table 75. Germany Hormone Deficiency, by Symptoms USD Million (2016-2021)
  • Table 76. France Hormone Deficiency, by Application USD Million (2016-2021)
  • Table 77. France Hormone Deficiency, by Medication USD Million (2016-2021)
  • Table 78. France Hormone Deficiency, by Types of Hormonal Disorders USD Million (2016-2021)
  • Table 79. France Hormone Deficiency, by Symptoms USD Million (2016-2021)
  • Table 80. Italy Hormone Deficiency, by Application USD Million (2016-2021)
  • Table 81. Italy Hormone Deficiency, by Medication USD Million (2016-2021)
  • Table 82. Italy Hormone Deficiency, by Types of Hormonal Disorders USD Million (2016-2021)
  • Table 83. Italy Hormone Deficiency, by Symptoms USD Million (2016-2021)
  • Table 84. United Kingdom Hormone Deficiency, by Application USD Million (2016-2021)
  • Table 85. United Kingdom Hormone Deficiency, by Medication USD Million (2016-2021)
  • Table 86. United Kingdom Hormone Deficiency, by Types of Hormonal Disorders USD Million (2016-2021)
  • Table 87. United Kingdom Hormone Deficiency, by Symptoms USD Million (2016-2021)
  • Table 88. Netherlands Hormone Deficiency, by Application USD Million (2016-2021)
  • Table 89. Netherlands Hormone Deficiency, by Medication USD Million (2016-2021)
  • Table 90. Netherlands Hormone Deficiency, by Types of Hormonal Disorders USD Million (2016-2021)
  • Table 91. Netherlands Hormone Deficiency, by Symptoms USD Million (2016-2021)
  • Table 92. Rest of Europe Hormone Deficiency, by Application USD Million (2016-2021)
  • Table 93. Rest of Europe Hormone Deficiency, by Medication USD Million (2016-2021)
  • Table 94. Rest of Europe Hormone Deficiency, by Types of Hormonal Disorders USD Million (2016-2021)
  • Table 95. Rest of Europe Hormone Deficiency, by Symptoms USD Million (2016-2021)
  • Table 96. MEA Hormone Deficiency, by Country USD Million (2016-2021)
  • Table 97. MEA Hormone Deficiency, by Application USD Million (2016-2021)
  • Table 98. MEA Hormone Deficiency, by Medication USD Million (2016-2021)
  • Table 99. MEA Hormone Deficiency, by Types of Hormonal Disorders USD Million (2016-2021)
  • Table 100. MEA Hormone Deficiency, by Symptoms USD Million (2016-2021)
  • Table 101. Middle East Hormone Deficiency, by Application USD Million (2016-2021)
  • Table 102. Middle East Hormone Deficiency, by Medication USD Million (2016-2021)
  • Table 103. Middle East Hormone Deficiency, by Types of Hormonal Disorders USD Million (2016-2021)
  • Table 104. Middle East Hormone Deficiency, by Symptoms USD Million (2016-2021)
  • Table 105. Africa Hormone Deficiency, by Application USD Million (2016-2021)
  • Table 106. Africa Hormone Deficiency, by Medication USD Million (2016-2021)
  • Table 107. Africa Hormone Deficiency, by Types of Hormonal Disorders USD Million (2016-2021)
  • Table 108. Africa Hormone Deficiency, by Symptoms USD Million (2016-2021)
  • Table 109. North America Hormone Deficiency, by Country USD Million (2016-2021)
  • Table 110. North America Hormone Deficiency, by Application USD Million (2016-2021)
  • Table 111. North America Hormone Deficiency, by Medication USD Million (2016-2021)
  • Table 112. North America Hormone Deficiency, by Types of Hormonal Disorders USD Million (2016-2021)
  • Table 113. North America Hormone Deficiency, by Symptoms USD Million (2016-2021)
  • Table 114. United States Hormone Deficiency, by Application USD Million (2016-2021)
  • Table 115. United States Hormone Deficiency, by Medication USD Million (2016-2021)
  • Table 116. United States Hormone Deficiency, by Types of Hormonal Disorders USD Million (2016-2021)
  • Table 117. United States Hormone Deficiency, by Symptoms USD Million (2016-2021)
  • Table 118. Canada Hormone Deficiency, by Application USD Million (2016-2021)
  • Table 119. Canada Hormone Deficiency, by Medication USD Million (2016-2021)
  • Table 120. Canada Hormone Deficiency, by Types of Hormonal Disorders USD Million (2016-2021)
  • Table 121. Canada Hormone Deficiency, by Symptoms USD Million (2016-2021)
  • Table 122. Mexico Hormone Deficiency, by Application USD Million (2016-2021)
  • Table 123. Mexico Hormone Deficiency, by Medication USD Million (2016-2021)
  • Table 124. Mexico Hormone Deficiency, by Types of Hormonal Disorders USD Million (2016-2021)
  • Table 125. Mexico Hormone Deficiency, by Symptoms USD Million (2016-2021)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Hormone Deficiency: by Application(USD Million)
  • Table 138. Hormone Deficiency Hospitals , by Region USD Million (2022-2027)
  • Table 139. Hormone Deficiency Clinics , by Region USD Million (2022-2027)
  • Table 140. Hormone Deficiency: by Medication(USD Million)
  • Table 141. Hormone Deficiency Genotropin , by Region USD Million (2022-2027)
  • Table 142. Hormone Deficiency Humatrope , by Region USD Million (2022-2027)
  • Table 143. Hormone Deficiency Norditropin , by Region USD Million (2022-2027)
  • Table 144. Hormone Deficiency Other , by Region USD Million (2022-2027)
  • Table 145. Hormone Deficiency: by Types of Hormonal Disorders(USD Million)
  • Table 146. Hormone Deficiency Adrenal , by Region USD Million (2022-2027)
  • Table 147. Hormone Deficiency Parathyroid , by Region USD Million (2022-2027)
  • Table 148. Hormone Deficiency Pancreas , by Region USD Million (2022-2027)
  • Table 149. Hormone Deficiency Pituitary , by Region USD Million (2022-2027)
  • Table 150. Hormone Deficiency Thyroid , by Region USD Million (2022-2027)
  • Table 151. Hormone Deficiency: by Symptoms(USD Million)
  • Table 152. Hormone Deficiency Dry skin , by Region USD Million (2022-2027)
  • Table 153. Hormone Deficiency Puffy face , by Region USD Million (2022-2027)
  • Table 154. Hormone Deficiency Frequent urination , by Region USD Million (2022-2027)
  • Table 155. Hormone Deficiency Depression , by Region USD Million (2022-2027)
  • Table 156. Hormone Deficiency Infertility , by Region USD Million (2022-2027)
  • Table 157. South America Hormone Deficiency, by Country USD Million (2022-2027)
  • Table 158. South America Hormone Deficiency, by Application USD Million (2022-2027)
  • Table 159. South America Hormone Deficiency, by Medication USD Million (2022-2027)
  • Table 160. South America Hormone Deficiency, by Types of Hormonal Disorders USD Million (2022-2027)
  • Table 161. South America Hormone Deficiency, by Symptoms USD Million (2022-2027)
  • Table 162. Brazil Hormone Deficiency, by Application USD Million (2022-2027)
  • Table 163. Brazil Hormone Deficiency, by Medication USD Million (2022-2027)
  • Table 164. Brazil Hormone Deficiency, by Types of Hormonal Disorders USD Million (2022-2027)
  • Table 165. Brazil Hormone Deficiency, by Symptoms USD Million (2022-2027)
  • Table 166. Argentina Hormone Deficiency, by Application USD Million (2022-2027)
  • Table 167. Argentina Hormone Deficiency, by Medication USD Million (2022-2027)
  • Table 168. Argentina Hormone Deficiency, by Types of Hormonal Disorders USD Million (2022-2027)
  • Table 169. Argentina Hormone Deficiency, by Symptoms USD Million (2022-2027)
  • Table 170. Rest of South America Hormone Deficiency, by Application USD Million (2022-2027)
  • Table 171. Rest of South America Hormone Deficiency, by Medication USD Million (2022-2027)
  • Table 172. Rest of South America Hormone Deficiency, by Types of Hormonal Disorders USD Million (2022-2027)
  • Table 173. Rest of South America Hormone Deficiency, by Symptoms USD Million (2022-2027)
  • Table 174. Asia Pacific Hormone Deficiency, by Country USD Million (2022-2027)
  • Table 175. Asia Pacific Hormone Deficiency, by Application USD Million (2022-2027)
  • Table 176. Asia Pacific Hormone Deficiency, by Medication USD Million (2022-2027)
  • Table 177. Asia Pacific Hormone Deficiency, by Types of Hormonal Disorders USD Million (2022-2027)
  • Table 178. Asia Pacific Hormone Deficiency, by Symptoms USD Million (2022-2027)
  • Table 179. China Hormone Deficiency, by Application USD Million (2022-2027)
  • Table 180. China Hormone Deficiency, by Medication USD Million (2022-2027)
  • Table 181. China Hormone Deficiency, by Types of Hormonal Disorders USD Million (2022-2027)
  • Table 182. China Hormone Deficiency, by Symptoms USD Million (2022-2027)
  • Table 183. Japan Hormone Deficiency, by Application USD Million (2022-2027)
  • Table 184. Japan Hormone Deficiency, by Medication USD Million (2022-2027)
  • Table 185. Japan Hormone Deficiency, by Types of Hormonal Disorders USD Million (2022-2027)
  • Table 186. Japan Hormone Deficiency, by Symptoms USD Million (2022-2027)
  • Table 187. India Hormone Deficiency, by Application USD Million (2022-2027)
  • Table 188. India Hormone Deficiency, by Medication USD Million (2022-2027)
  • Table 189. India Hormone Deficiency, by Types of Hormonal Disorders USD Million (2022-2027)
  • Table 190. India Hormone Deficiency, by Symptoms USD Million (2022-2027)
  • Table 191. South Korea Hormone Deficiency, by Application USD Million (2022-2027)
  • Table 192. South Korea Hormone Deficiency, by Medication USD Million (2022-2027)
  • Table 193. South Korea Hormone Deficiency, by Types of Hormonal Disorders USD Million (2022-2027)
  • Table 194. South Korea Hormone Deficiency, by Symptoms USD Million (2022-2027)
  • Table 195. Australia Hormone Deficiency, by Application USD Million (2022-2027)
  • Table 196. Australia Hormone Deficiency, by Medication USD Million (2022-2027)
  • Table 197. Australia Hormone Deficiency, by Types of Hormonal Disorders USD Million (2022-2027)
  • Table 198. Australia Hormone Deficiency, by Symptoms USD Million (2022-2027)
  • Table 199. Rest of Asia-Pacific Hormone Deficiency, by Application USD Million (2022-2027)
  • Table 200. Rest of Asia-Pacific Hormone Deficiency, by Medication USD Million (2022-2027)
  • Table 201. Rest of Asia-Pacific Hormone Deficiency, by Types of Hormonal Disorders USD Million (2022-2027)
  • Table 202. Rest of Asia-Pacific Hormone Deficiency, by Symptoms USD Million (2022-2027)
  • Table 203. Europe Hormone Deficiency, by Country USD Million (2022-2027)
  • Table 204. Europe Hormone Deficiency, by Application USD Million (2022-2027)
  • Table 205. Europe Hormone Deficiency, by Medication USD Million (2022-2027)
  • Table 206. Europe Hormone Deficiency, by Types of Hormonal Disorders USD Million (2022-2027)
  • Table 207. Europe Hormone Deficiency, by Symptoms USD Million (2022-2027)
  • Table 208. Germany Hormone Deficiency, by Application USD Million (2022-2027)
  • Table 209. Germany Hormone Deficiency, by Medication USD Million (2022-2027)
  • Table 210. Germany Hormone Deficiency, by Types of Hormonal Disorders USD Million (2022-2027)
  • Table 211. Germany Hormone Deficiency, by Symptoms USD Million (2022-2027)
  • Table 212. France Hormone Deficiency, by Application USD Million (2022-2027)
  • Table 213. France Hormone Deficiency, by Medication USD Million (2022-2027)
  • Table 214. France Hormone Deficiency, by Types of Hormonal Disorders USD Million (2022-2027)
  • Table 215. France Hormone Deficiency, by Symptoms USD Million (2022-2027)
  • Table 216. Italy Hormone Deficiency, by Application USD Million (2022-2027)
  • Table 217. Italy Hormone Deficiency, by Medication USD Million (2022-2027)
  • Table 218. Italy Hormone Deficiency, by Types of Hormonal Disorders USD Million (2022-2027)
  • Table 219. Italy Hormone Deficiency, by Symptoms USD Million (2022-2027)
  • Table 220. United Kingdom Hormone Deficiency, by Application USD Million (2022-2027)
  • Table 221. United Kingdom Hormone Deficiency, by Medication USD Million (2022-2027)
  • Table 222. United Kingdom Hormone Deficiency, by Types of Hormonal Disorders USD Million (2022-2027)
  • Table 223. United Kingdom Hormone Deficiency, by Symptoms USD Million (2022-2027)
  • Table 224. Netherlands Hormone Deficiency, by Application USD Million (2022-2027)
  • Table 225. Netherlands Hormone Deficiency, by Medication USD Million (2022-2027)
  • Table 226. Netherlands Hormone Deficiency, by Types of Hormonal Disorders USD Million (2022-2027)
  • Table 227. Netherlands Hormone Deficiency, by Symptoms USD Million (2022-2027)
  • Table 228. Rest of Europe Hormone Deficiency, by Application USD Million (2022-2027)
  • Table 229. Rest of Europe Hormone Deficiency, by Medication USD Million (2022-2027)
  • Table 230. Rest of Europe Hormone Deficiency, by Types of Hormonal Disorders USD Million (2022-2027)
  • Table 231. Rest of Europe Hormone Deficiency, by Symptoms USD Million (2022-2027)
  • Table 232. MEA Hormone Deficiency, by Country USD Million (2022-2027)
  • Table 233. MEA Hormone Deficiency, by Application USD Million (2022-2027)
  • Table 234. MEA Hormone Deficiency, by Medication USD Million (2022-2027)
  • Table 235. MEA Hormone Deficiency, by Types of Hormonal Disorders USD Million (2022-2027)
  • Table 236. MEA Hormone Deficiency, by Symptoms USD Million (2022-2027)
  • Table 237. Middle East Hormone Deficiency, by Application USD Million (2022-2027)
  • Table 238. Middle East Hormone Deficiency, by Medication USD Million (2022-2027)
  • Table 239. Middle East Hormone Deficiency, by Types of Hormonal Disorders USD Million (2022-2027)
  • Table 240. Middle East Hormone Deficiency, by Symptoms USD Million (2022-2027)
  • Table 241. Africa Hormone Deficiency, by Application USD Million (2022-2027)
  • Table 242. Africa Hormone Deficiency, by Medication USD Million (2022-2027)
  • Table 243. Africa Hormone Deficiency, by Types of Hormonal Disorders USD Million (2022-2027)
  • Table 244. Africa Hormone Deficiency, by Symptoms USD Million (2022-2027)
  • Table 245. North America Hormone Deficiency, by Country USD Million (2022-2027)
  • Table 246. North America Hormone Deficiency, by Application USD Million (2022-2027)
  • Table 247. North America Hormone Deficiency, by Medication USD Million (2022-2027)
  • Table 248. North America Hormone Deficiency, by Types of Hormonal Disorders USD Million (2022-2027)
  • Table 249. North America Hormone Deficiency, by Symptoms USD Million (2022-2027)
  • Table 250. United States Hormone Deficiency, by Application USD Million (2022-2027)
  • Table 251. United States Hormone Deficiency, by Medication USD Million (2022-2027)
  • Table 252. United States Hormone Deficiency, by Types of Hormonal Disorders USD Million (2022-2027)
  • Table 253. United States Hormone Deficiency, by Symptoms USD Million (2022-2027)
  • Table 254. Canada Hormone Deficiency, by Application USD Million (2022-2027)
  • Table 255. Canada Hormone Deficiency, by Medication USD Million (2022-2027)
  • Table 256. Canada Hormone Deficiency, by Types of Hormonal Disorders USD Million (2022-2027)
  • Table 257. Canada Hormone Deficiency, by Symptoms USD Million (2022-2027)
  • Table 258. Mexico Hormone Deficiency, by Application USD Million (2022-2027)
  • Table 259. Mexico Hormone Deficiency, by Medication USD Million (2022-2027)
  • Table 260. Mexico Hormone Deficiency, by Types of Hormonal Disorders USD Million (2022-2027)
  • Table 261. Mexico Hormone Deficiency, by Symptoms USD Million (2022-2027)
  • Table 262. Research Programs/Design for This Report
  • Table 263. Key Data Information from Secondary Sources
  • Table 264. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hormone Deficiency: by Application USD Million (2016-2021)
  • Figure 5. Global Hormone Deficiency: by Medication USD Million (2016-2021)
  • Figure 6. Global Hormone Deficiency: by Types of Hormonal Disorders USD Million (2016-2021)
  • Figure 7. Global Hormone Deficiency: by Symptoms USD Million (2016-2021)
  • Figure 8. South America Hormone Deficiency Share (%), by Country
  • Figure 9. Asia Pacific Hormone Deficiency Share (%), by Country
  • Figure 10. Europe Hormone Deficiency Share (%), by Country
  • Figure 11. MEA Hormone Deficiency Share (%), by Country
  • Figure 12. North America Hormone Deficiency Share (%), by Country
  • Figure 13. Global Hormone Deficiency share by Players 2021 (%)
  • Figure 14. Global Hormone Deficiency share by Players (Top 3) 2021(%)
  • Figure 15. Global Hormone Deficiency share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Merck Serono (Germany) Revenue, Net Income and Gross profit
  • Figure 18. Merck Serono (Germany) Revenue: by Geography 2021
  • Figure 19. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 20. Pfizer (United States) Revenue: by Geography 2021
  • Figure 21. Novo Nordisk (Denmark) Revenue, Net Income and Gross profit
  • Figure 22. Novo Nordisk (Denmark) Revenue: by Geography 2021
  • Figure 23. F. Hoffmann-La Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. F. Hoffmann-La Roche (Switzerland) Revenue: by Geography 2021
  • Figure 25. Anhui Anke Biotechnology (Group) (China) Revenue, Net Income and Gross profit
  • Figure 26. Anhui Anke Biotechnology (Group) (China) Revenue: by Geography 2021
  • Figure 27. BioPartners (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. BioPartners (Switzerland) Revenue: by Geography 2021
  • Figure 29. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 30. Eli Lilly (United States) Revenue: by Geography 2021
  • Figure 31. Ferring Pharmaceuticals (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Ferring Pharmaceuticals (Switzerland) Revenue: by Geography 2021
  • Figure 33. GeneScience Pharmaceuticals (China) Revenue, Net Income and Gross profit
  • Figure 34. GeneScience Pharmaceuticals (China) Revenue: by Geography 2021
  • Figure 35. Ipsen (France) Revenue, Net Income and Gross profit
  • Figure 36. Ipsen (France) Revenue: by Geography 2021
  • Figure 37. Teva Pharmaceutical Industries (Israel) Revenue, Net Income and Gross profit
  • Figure 38. Teva Pharmaceutical Industries (Israel) Revenue: by Geography 2021
  • Figure 39. Global Hormone Deficiency: by Application USD Million (2022-2027)
  • Figure 40. Global Hormone Deficiency: by Medication USD Million (2022-2027)
  • Figure 41. Global Hormone Deficiency: by Types of Hormonal Disorders USD Million (2022-2027)
  • Figure 42. Global Hormone Deficiency: by Symptoms USD Million (2022-2027)
  • Figure 43. South America Hormone Deficiency Share (%), by Country
  • Figure 44. Asia Pacific Hormone Deficiency Share (%), by Country
  • Figure 45. Europe Hormone Deficiency Share (%), by Country
  • Figure 46. MEA Hormone Deficiency Share (%), by Country
  • Figure 47. North America Hormone Deficiency Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Merck Serono (Germany)
  • Pfizer (United States)
  • Novo Nordisk (Denmark)
  • F. Hoffmann-La Roche (Switzerland)
  • Anhui Anke Biotechnology (Group) (China)
  • BioPartners (Switzerland)
  • Eli Lilly (United States)
  • Ferring Pharmaceuticals (Switzerland)
  • GeneScience Pharmaceuticals (China)
  • Ipsen (France)
  • Teva Pharmaceutical Industries (Israel)
Select User Access Type

Key Highlights of Report


Jul 2022 209 Pages 89 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hormone Deficiency Market Quantitative research analysis
Global Hormone Deficiency Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Merck Serono (Germany), Pfizer (United States), Novo Nordisk (Denmark), F. Hoffmann-La Roche (Switzerland), Anhui Anke Biotechnology (Group) (China), BioPartners (Switzerland), Eli Lilly (United States), Ferring Pharmaceuticals (Switzerland), GeneScience Pharmaceuticals (China), Ipsen (France) and Teva Pharmaceutical Industries (Israel) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increase In The Number Of Research And Development Activities" is seen as one of major influencing trends for Hormone Deficiency Market during projected period 2021-2027.
The Hormone Deficiency market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Hormone Deficiency Market Report?

Have a Query? Click Here

Other Related Reports

Stephania Extract Comprehensive Study by Type (Tablet, Capsule, Injection), Distribution Channel (Online, Offline), End User (Household, Hospital, Clinic, Pharmaceutical, Others) Players and Region -...
$ 3500
Probiotics Based Dietary Supplement Comprehensive Study by Type (Capsules and Pills, Powders, Fermented Foods), Application (Immune System Support, Vaginal Health, Skin Health), Form (Capsules, Chewa...
$ 3800
Clascoterone Comprehensive Study by Type (97% purity, 98% purity, 99% purity), Application (Acne, Hair loss), Distribution Channel (Direct, Indirect) Players and Region - Global Market Outlook to 202...
$ 3800
Gelatin Peptide Plasma Substitute Comprehensive Study by Type (Urea Bridged Gelatin Polypeptide, Succinic Acid Gelatin Polypeptide, Poly Gelatin Peptide), Application (Hospital, Clinic, Other) Player...
$ 3800
Dolutegravir Sodium- Comprehensive Study by Type (Bottled Packaging, Film Coated Packaging), Application (AIDS Adult Patients, AIDS Children over 12 Years Old), By Structure (2D, 3D), By Products (TI...
$ 3800
Pharma 4.0 Comprehensive Study by Application (Big Data Analytics, Virtual reality, Internet of things (IoT), Machine-to-Machine (M2M), Cloud Computing & Automation, Cyber-Physical Systems, Others), ...
$ 3800